Experimental drug could spur immunotherapy response in patients with non-small cell lung cancer 2022 | United States

 The global non small cell lung cancer (NSCLC) therapeutics market size was valued at USD 16,011.7 Million in 2018 and is projected to reach USD 43,713.1 Million by the end of 2026, exhibiting a CAGR of 13.4% in the forecast period (2019-2026).

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non-small cell lung cancers (NSCLCs) to respond to an immune checkpoint blockade (ICB), a therapy that harnesses the immune system to fight malignant tumors. The findings, derived from a preclinical lab model and published in Cell Reports Medicine, could lead to more effective treatments for this subset of NSCLCs.

Get a Sample Copy of the Report at – https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100484

“These results provide hope that we can significantly enhance the efficacy of immune checkpoint blockade in non-small cell lung cancer patients for whom immunotherapies have not previously been effective,” said study leader Rolf Brekken, Ph.D., Professor of Surgery, Deputy Director of the Hamon Center for Therapeutic Oncology Research, and member of the Harold C. Simmons Comprehensive Cancer Center.

ICB has had a significant impact on outcomes in a variety of cancers since the first in this class of immunotherapies was approved by the U.S. Food and Drug Administration in 2011. Patients who respond to these treatments tend to survive significantly longer compared to those treated with chemotherapy, radiation, and/or surgery.

NSCLC patients whose cancers are driven by mutations in a gene called KRAS usually have a high response rate to ICBs. However, Dr. Brekken explained, about 20% of NSCLC tumors also carry mutations in a gene known as STK11/LKB1, which is associated with poor response to ICB therapy. The reason for this phenomenon has been unclear, preventing researchers from addressing it.

Key players covered in the global Non-Small Cell Lung Cancer Therapeutics Market research report:

  • Genentech (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astellas
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc. (Takeda)
  • Merck Sharp & Dohme Corp.

Key Stakeholders

  • Natural substance providers
  • Merchants/brokers/wholesalers/providers
  • Administrative bodies, including government organizations and NGO
  • Business innovative work (RandD) establishments
  • Merchants and exporters
  • Government associations, research associations, and counseling firms
  • Exchange affiliations and industry bodies
  • End-use enterprises

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Comments

Post a Comment

Popular posts from this blog

US Market Trends For Computer-Assisted & Robotics-Assisted Surgery

  In the medical industry, adoption of new cutting-edge technology is slow compared to other industries, such as the automotive industry. 1  Computer-assisted and robotic-assisted surgery (CAS and RAS, respectively) have been around for decades, yet a small percentage of procedures performed take advantage of the innovative solutions available on the market today. In coming years, the number of procedures using robotics and surgical navigation is predicted to increase at a double-digit rate year over year to reach over 6 million procedures by 2028. 2  This rise in CAS and RAS can be attributed to the predicted increase in the utilization of navigation systems and robotic devices as more companies launch new or next-generation systems for assisted surgery. Reasons For Slow CAS And RAS Adoption Some argue that using CAS and RAS is not worth the time and monetary investment, as using this technology often increases procedure planning time and reduces the number of procedures...
Read more

Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer

  Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer   Health Canada approved nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer prior to surgery. Nivolumab (Opdivo) plus platinum-doublet chemotherapy has been approved by Health Canada for the treatment of certain patients with resectable non–small cell lung cancer, according to Bristol Meyers Squibb. The approval was based on results from the phase 3 CheckMate 816 trial (NCT02998528), in which neoadjuvant nivolumab plus chemotherapy resulted in a 37% reduction in risk of disease progression, recurrence, or death vs chemotherapy alone among patients with resectable NSCLC (HR, 0.63; 97.38%, 0.43-0.91;  P  = .005). The median event-free survival (EFS) with nivolumab/chemotherapy was 31.6 months vs 20.8 months with chemotherapy alone. Improvement in the rate of pathologica...
Read more

USA – Overview of Prothrombin Complex Concentrate Industry and Healthcare Statistics in 2022

Image
The global   Prothrombin Complex Concentrate (PCC) market size  was valued at USD 695.3 million in 2019 and is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6 % during the forecast period Abstract Left ventricular assist devices (LVADs) require careful therapeutic anticoagulation with warfarin to prevent pump thrombosis. However, the best method to reverse warfarin for elective LVAD conversion surgery with massive bleeding remains unclear. We report the case of a 39-year-old Japanese man who was administered a four-factor prothrombin complex concentrate (4F-PCC) as warfarin reversal when he underwent conversion surgery from paracorporeal LVAD to implantable LVAD. 4F-PCC with co-administration of vitamin K reduced the international normalized ratio and R time in TEG6s (Haemonetics Corporation, USA) immediately. The effect was prolonged, and good hemostasis was achieved. 4F-PCC with vitamin K provided good hemostasis in our patient; therefore, 4F-PCC co...
Read more